| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $1 ) |
| | 2022 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | | | CAN | R21CA226321 | Analysis of T-cell antigen diversity by deep sequencing | 000 | 1 | NIH | 9/26/2022 | $1 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 000 | 12 | NIH | 1/3/2020 | $0 |
| | 2020 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R21CA226321 | Analysis of T-cell antigen diversity by deep sequencing | 000 | 1 | NIH | 11/20/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = -$975,373 ) |
| | 2019 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 000 | 12 | NIH | 11/29/2018 | -$264,811 |
| | 2019 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | U24CA210952 | Integrative miRNA data analysis for clinical cancer genomics | 000 | 3 | NIH | 12/19/2018 | -$397,386 |
| | 2019 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | U24CA210952 | Integrative miRNA data analysis for clinical cancer genomics | 004 | 3 | NIH | 9/3/2019 | -$1 |
| | 2019 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R21CA226321 | Analysis of T-cell antigen diversity by deep sequencing | 000 | 1 | NIH | 12/19/2018 | -$77,856 |
| | 2019 | 2017 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | U24CA210952 | Integrative miRNA data analysis for clinical cancer genomics | 003 | 2 | NIH | 9/3/2019 | -$235,319 |
|
| Issue Date FY: 2018 ( Subtotal = $628,332 ) |
| | 2018 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 000 | 12 | NIH | 2/26/2018 | $238,331 |
| | 2018 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 001 | 12 | NIH | 5/23/2018 | $26,481 |
| | 2018 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | U24CA210952 | Integrative miRNA data analysis for clinical cancer genomics | 000 | 3 | NIH | 9/6/2018 | $397,387 |
| | 2018 | 2018 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R21CA226321 | Analysis of T-cell antigen diversity by deep sequencing | 000 | 1 | NIH | 3/15/2018 | $107,091 |
| | 2018 | 2016 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01HG007182 | De Novo Assembly Tools: Research with Unbiased Engines - Renewal (DNA-TRUER) | 000 | 3 | NIH | 1/4/2018 | -$140,958 |
|
| Issue Date FY: 2017 ( Subtotal = $903,293 ) |
| | 2017 | 2017 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01HG007182 | De Novo Assembly Tools: Research with Unbiased Engines - Renewal (DNA-TRUER) | 000 | 4 | NIH | 8/29/2017 | $244,045 |
| | 2017 | 2017 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | U24CA210952 | Integrative miRNA data analysis for clinical cancer genomics | 000 | 2 | NIH | 8/3/2017 | $398,402 |
| | 2017 | 2017 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 001 | 11 | NIH | 2/15/2017 | $260,847 |
| | 2017 | 2015 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 000 | 5 | NIH | 12/1/2016 | $0 |
| | 2017 | 2015 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R21CA187910 | Identification and annotation of 3' UTR ends using RNA-seq data | 000 | 2 | NIH | 12/9/2016 | $0 |
| | 2017 | 2014 | BRITISH COLUMBIA CANCER AGENCY BRANCH | 600 10TH AVE W | VANCOUVER | BC | V5Z 4E6 | | CAN | R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 000 | 10 | NIH | 12/2/2016 | -$1 |
|
| Issue Date FY: 2016 ( Subtotal = $292,844 ) |
| | 2016 | 2016 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R01HG007182 | De Novo Assembly Tools: Research with Unbiased Engines - Renewal (DNA-TRUER) | 000 | 3 | NIH | 2/3/2016 | $249,665 |
| | 2016 | 2016 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R21CA187910 | Identification and annotation of 3' UTR ends using RNA-seq data | 000 | 2 | NIH | 1/8/2016 | $43,179 |
|
| Issue Date FY: 2015 ( Subtotal = $569,991 ) |
| | 2015 | 2015 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 001 | 5 | NIH | 9/21/2015 | $219,276 |
| | 2015 | 2015 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R21CA187910 | Identification and annotation of 3' UTR ends using RNA-seq data | 000 | 2 | NIH | 7/23/2015 | $101,050 |
| | 2015 | 2015 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R01HG007182 | De Novo Assembly Tools: Research with Unbiased Engines - Renewal (DNA-TRUER) | 000 | 2 | NIH | 1/30/2015 | $249,665 |
| | 2015 | 2013 | BRITISH COLUMBIA CANCER AGENCY | 660 WEST 10TH AVENUE | VANCOUVER | | 00000 | | | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 000 | 5 | NIH | 8/3/2015 | $0 |
| | 2015 | 2013 | BRITISH COLUMBIA CANCER AGENCY | 660 WEST 10TH AVENUE | VANCOUVER | | 00000 | | | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 000 | 5 | NIH | 8/3/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $649,176 ) |
| | 2014 | 2014 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 000 | 5 | NIH | 9/12/2014 | $296,351 |
| | 2014 | 2014 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R01HG007182 | De Novo Assembly Tools: Research with Unbiased Engines - Renewal (DNA-TRUER) | 000 | 1 | NIH | 3/4/2014 | $249,465 |
| | 2014 | 2014 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R21CA187910 | Identification and annotation of 3' UTR ends using RNA-seq data | 000 | 1 | NIH | 9/17/2014 | $103,360 |
|
| Issue Date FY: 2013 ( Subtotal = $2,342,431 ) |
| | 2013 | 2013 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 001 | 5 | NIH | 9/20/2013 | $300,000 |
| | 2013 | 2013 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 000 | 5 | NIH | 7/26/2013 | $1,819,783 |
| | 2013 | 2013 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R01GM094146 | CHROMATIN MAINTENANCE AND SISTER CHROMATID DIFFERENTIATION | 000 | 4 | NIH | 8/30/2013 | $222,648 |
|
| Issue Date FY: 2012 ( Subtotal = $2,463,099 ) |
| | 2012 | 2012 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | R01GM094146 | CHROMATIN MAINTENANCE AND SISTER CHROMATID DIFFERENTIATION | 000 | 3 | NIH | 8/23/2012 | $234,495 |
| | 2012 | 2012 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 001 | 4 | NIH | 9/7/2012 | $98,701 |
| | 2012 | 2012 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U24CA143866 | Cancer transcriptome characterization using massively parallel DNA sequencing | 000 | 4 | NIH | 8/1/2012 | $1,998,049 |
| | 2012 | 2012 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U10CA142559 | TO ESTABLISH THE BC CANCER AGENCY - VANCOUVER CENTRE AS A MAJOR SWOG CENTRE | 000 | 3 | NIH | 1/5/2012 | $131,854 |
| | 2012 | 2012 | BRITISH COLUMBIA CANCER AGENCY | 660 WEST 10TH AVENUE | VANCOUVER | | 00000 | | | U10CA142559 | TO ESTABLISH THE BC CANCER AGENCY - VANCOUVER CENTRE AS A MAJOR SWOG CENTRE | 001 | 3 | NIH | 8/6/2012 | $0 |
| | 2012 | 2010 | BRITISH COLUMBIA CANCER AGENCY | 660 WEST 10TH AVENUE | VANCOUVER | | 00000 | | | R21CA139814 | 18F-FLUOROESTRADIOL PET/CT GUIDED FULVESTRANT THERAPY FOR PATIENTS WITH RECURRENT | 000 | 2 | NIH | 2/2/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $2,390,171 ) (Continued on the next page) |
| | 2011 | 2011 | BRITISH COLUMBIA CANCER AGENCY | 600 West 10th Avenue | VANCOUVER | | | | CAN | U10CA142559 | TO ESTABLISH THE BC CANCER AGENCY - VANCOUVER CENTRE AS A MAJOR SWOG CENTRE | 000 | 2 | NIH | 1/26/2011 | $188,304 |
|
